TrueCAGR

Lupin Ltd

NSE: LUPINBSE: 500257ISIN INE326A01037Face value ₹2consolidated
₹2,010
+0.55% · 2026-11-20 · 52-wk ₹1,925–₹2,515
Source: BSE filings · Financials to FY2026 · 8 years of history · Data last updated: results filed 4 Nov 2026, prices to 20 Nov 2026 · How we calculate thisconsolidatedstandalone
Section 02 · Synthesis

What stands out?

The strongest observations the engine found, ranked. Every line is generated from the filed numbers by a fixed rule — no opinion, no estimate.

StrengthConcernWatchContext
StrengthTalking point

Profit outpacing revenue

Profit grew 62.0% while revenue grew 23.1%, so the company kept more of each rupee of revenue as profit.

Net profit growth+62.0%Revenue growth+23.1%

Importance 72 / 95 · growth

WatchTalking point

Volatile earnings

Profit has swung sharply over 7 years (from ₹-1,509 to ₹5,355) — one year is a weak guide to the earnings power.

Importance 65 / 95 · growth

WatchTalking point

Cash conversion trending down

Cash conversion (CFO ÷ profit) has averaged 1.11× over the last 3 profit-making years versus 2.66× before that.

Importance 64 / 95 · cash quality

StrengthTalking point

Margins at a multi-year high

EBITDA margin of 33.1% is the widest in 7 years (prior range 2.6% to 24.1%).

Importance 62 / 95 · profitability

Section 03 · The company

Who is this company?

Classified by the exchange under Healthcare › Healthcare › Pharmaceuticals & Biotechnology › Pharmaceuticals.

Market cap
₹91,897 cr
FY2026 revenue
₹27,958 cr
FY2026 net profit
₹5,355 cr
Net worth
₹22,513 cr
Total debt
₹5,910 cr
EPS (basic)
₹116.75
Listed
NSE · BSE
Reporting
Ind-ASApr–Mar

Peer set used on this page: 12 pharmaceuticals.

Section 04 · Business performance

Is the business growing?

Revenue grew 7.9% a year over 7 years, from ₹16,369 cr in FY2019 to ₹27,958 cr in FY2026. Net profit grew 36.2% a year over the same period.

Revenue & net profit — FY19 to FY26₹ crore · consolidated
₹'000 cr08152330036REVENUENET PROFIT16k615FY1915k-270FY2015k1,228FY2116k-1,509FY2217k448FY2320k1,936FY2423k3,306FY2528k5,355FY26
RevenueNet profit
Strength

Profit grew 62.0% while revenue grew 23.1%, so the company kept more of each rupee of revenue as profit.

Rule PROFIT_FASTER_THAN_REVENUE

Revenue growth per year
+7.9%over 7 years (FY19–FY26)
Revenue growth
+23.1%vs last year
Net profit growth
+62.0%vs last year
Change in net profit since FY19
+770%

Profit has swung sharply over 7 years (from ₹-1,509 to ₹5,355) — one year is a weak guide to the earnings power.

Over 7 years profit compounded at 36.2% a year while revenue compounded at 7.9% a year — though FY2024 saw a one-off step-change of 332% (a merger, restructuring or a recovery off a low base), so the compounding is uneven.

Net profit grew 62.0% year on year (FY2025 → FY2026).

Revenue grew 23.1% year on year (FY2025 → FY2026).

Revenue has compounded at 7.9% a year over 7 years (₹16,369 → ₹27,958) — steady rather than rapid.

Section 05 · Recent activity

What changed recently?

In Q2 FY27 (Jul–Sep 2026), revenue was ₹7,827 cr (up 11.1% on the same quarter last year) and net profit ₹1,155 cr (down 22.2%).

Quarterly results, the trailing-twelve-months snapshot, and verified corporate actions — kept separate from each other and from the annual story above. Every figure traces to a filed number; nothing here is external news or commentary.

Concern

Q2 FY27 net profit was ₹1,155 cr, down 22.2% from ₹1,485 cr a year earlier.

Rule QTR_PROFIT_GROWTH_YOY

Concern

Q2 FY27 EBITDA margin was 27.7%, down 6.76 percentage points from 34.5% a year earlier.

Rule QTR_MARGIN_CHANGED_YOY

Watch

Q2 FY27 net profit declined 22.2% while revenue grew 11.1% vs the same quarter last year — a gap of 33.3 percentage points.

Rule QTR_PROFIT_VS_REVENUE_GROWTH

A. Quarterly results

Latest quarters — Q3 '25 to Q2 '27₹ crore · consolidated
₹'000 cr02579012REVENUENET PROFIT6k859Q3 '256k782Q4 '256k1,221Q1 '267k1,485Q2 '267k1,181Q3 '267k1,469Q4 '268k1,417Q1 '278k1,155Q2 '27
RevenueNet profit
QuarterRevenueYoYNet profitYoYNet margin
Q3 FY255,768+11.0%859+38.8%14.9%
Q4 FY255,667+14.2%782+112.5%13.8%
Q1 FY266,268+11.9%1,221+51.6%19.5%
Q2 FY267,048+24.2%1,485+72.8%21.1%
Q3 FY267,168+24.3%1,181+37.5%16.5%
Q4 FY267,475+31.9%1,469+87.7%19.6%
Q1 FY278,277+32.0%1,417+16.0%17.1%
Q2 FY277,827+11.1%1,155−22.2%14.8%

B. TTM snapshot

Trailing twelve months to 30 Sept 2026 · sum of the last 4 contiguous quarters

Revenue
₹30,746 crTTM
EBITDA
₹9,754 crTTM
EBIT
₹8,055 crTTM
PBT
₹7,047 crTTM
Net profit
₹5,221 crTTM

C. Corporate actions

17 Jul 2026DividendFinal Dividend - Rs. - 18.0000 — ₹18.00/share
25 Jul 2025DividendFinal Dividend - Rs. - 12.0000 — ₹12.00/share
16 Jul 2024DividendFinal Dividend - Rs. - 8.0000 — ₹8.00/share
14 Jul 2023DividendFinal Dividend - Rs. - 4.0000 — ₹4.00/share
14 Jul 2022DividendFinal Dividend - Rs. - 4.0000 — ₹4.00/share
27 Jul 2021DividendFinal Dividend - Rs. - 6.5000 — ₹6.50/share
3 Aug 2020DividendFinal Dividend - Rs. - 6.0000 — ₹6.00/share
29 Jul 2019DividendFinal Dividend - Rs. - 5.0000 — ₹5.00/share
30 Jul 2018DividendDividend - Rs. - 5.0000 — ₹5.00/share
24 Jul 2017DividendDividend - Rs. - 7.5000 — ₹7.50/share
25 Jul 2016DividendDividend - Rs. - 7.5000 — ₹7.50/share
14 Jul 2015DividendDividend - Rs. - 7.5000 — ₹7.50/share
21 Jul 2014DividendFinal Dividend - Rs. - 3.0000 — ₹3.00/share
13 Feb 2014DividendInterim Dividend - Rs. - 3.0000 — ₹3.00/share
29 Jul 2013DividendDividend - Rs. - 4.0000 — ₹4.00/share
13 Jul 2012DividendDividend - Rs. - 3.2000 — ₹3.20/share
18 Jul 2011DividendDividend - Rs. - 3.0000 — ₹3.00/share
27 Aug 2010Stock splitStock Split From Rs.10/- to Rs.2/- — 10:2
19 Jul 2010DividendDividend - Rs. - 13.5000 — ₹13.50/share
20 Jul 2009DividendDividend - Rs. - 12.5000 — ₹12.50/share
11 Jul 2008DividendDividend - Rs. - 10.0000 — ₹10.00/share
10 Jul 2007DividendDividend - Rs. - 5.0000 — ₹5.00/share
24 Jan 2002DividendInterim Dividend - Rs. - 2.5000 — ₹2.50/share
29 Aug 2001DividendDividend - Rs. - 3.5000 — ₹3.50/share
16 Jul 2001OtherReduction of Capital
Section 06 · Business performance

Is it becoming more profitable?

EBITDA margin was 33.1% in FY2026, against 19.8% in FY2019. ROE was 26.9% and ROCE 31.0% in FY2026.

Margins — FY19 to FY26% of revenue · consolidated
-10%-5%0%5%10%15%20%25%30%35%33.1%18.9%FY19FY20FY21FY22FY23FY24FY25FY26
EBITDA marginNet margin
Strength

EBITDA margin of 33.1% is the widest in 7 years (prior range 2.6% to 24.1%).

Rule MARGIN_AT_MULTI_YEAR_HIGH

EBITDA margin now
33.1%
8-year range
2.6–33.1%
ROE FY2026
26.9%
ROCE FY2026
31.0%

ROE of 26.9% is the highest in 7 years (prior range -11.6% to 20.9%).

ROE of 26.9% is well above the pharmaceuticals median of 14.4%.

EBITDA margin improved from 24.1% to 33.1% of revenue.

ROE improved from 20.9% to 26.9% year on year.

Section 07 · Financial health

Is financial health improving?

Debt-to-equity was 0.26x in FY2026, against 0.60x in FY2019; interest coverage 18.10x. Operating cash flow was 1.41x net profit.

Net worth — FY19 to FY26₹ crore · consolidated
₹'000 cr010203014kFY1913kFY2014kFY2112kFY2213kFY2314kFY2417kFY2523kFY26
Net worth (shareholders' funds)
Watch

Cash conversion (CFO ÷ profit) has averaged 1.11× over the last 3 profit-making years versus 2.66× before that.

Rule CASH_CONVERSION_DETERIORATING

Operating cash flow vs net profit₹ crore · FY21–FY26
0k3k5k8k1k1kFY211k-2kFY222k448FY233k2kFY244303kFY258k5kFY26
Operating cash flowNet profit
Total debt
₹5,910 cr
Operating cash flow ÷ net profit
1.41×FY2026
Free cash flow
₹5,738 cr
Current ratio
1.90×

Total debt is down from ₹8,222 to ₹5,910 over 7 years (28.1% lower); debt-to-equity moved 0.60× → 0.26×.

Operating cash flow has matched or exceeded reported profit in 4 of the last 5 profit-making years (latest 1.41×).

Free cash flow has been positive in 5 of the last 6 years.

Section 08 · Relative position

How does it compare with peers?

Within its 12-company Pharmaceuticals peer group, it ranks 1 of 12 on return on equity and 4 of 12 on EBITDA margin. Its P/E of 17.6 compares with a peer median of 45.3.

Ranked against 12 pharmaceuticals (FY2026, consolidated).

Revenue growth

LUPIN · 2nd of 12 · set median 14.8%

GLENMARK27.5%LUPIN23.1%LAURUSLABS22.7%TORNTPHARM21.4%MANKIND17.0%ZYDUSLIFE16.8%DIVISLAB12.8%SUNPHARMA11.2%BIOCON10.9%AUROPHARMA6.1%DRREDDY3.2%CIPLA2.2%

EBITDA margin

LUPIN · 4th of 12 · set median 28.7%

DIVISLAB37.4%SUNPHARMA33.7%ZYDUSLIFE33.1%LUPIN33.1%TORNTPHARM31.9%GLENMARK29.6%MANKIND27.8%LAURUSLABS26.9%CIPLA24.0%DRREDDY23.2%BIOCON22.4%AUROPHARMA21.8%

Return on equity

LUPIN · 1st of 12 · set median 14.4%

LUPIN26.9%ZYDUSLIFE18.3%LAURUSLABS17.7%TORNTPHARM17.0%DIVISLAB16.2%SUNPHARMA14.7%GLENMARK14.1%MANKIND12.5%CIPLA11.7%DRREDDY11.5%AUROPHARMA9.9%BIOCON1.1%

P/E ratio

LUPIN · 1st of 12 · set median 45.3×

LUPIN17.6×AUROPHARMA26.2×ZYDUSLIFE28.1×CIPLA40.1×SUNPHARMA41.2×DRREDDY42.1×MANKIND48.5×GLENMARK51.5×TORNTPHARM75.8×DIVISLAB88.3×LAURUSLABS93.0×BIOCON174.3×
Context

ROE of 26.9% beats the pharmaceuticals median (14.4%) while P/B (4.08×) sits below it (4.74×).

Rule STRONG_RETURNS_AT_DISCOUNT

P / E
17.6×TTM to Sept 26
P / B
4.1×latest book
P / S
3.0×TTM sales
Earnings yield
5.7%TTM to Sept 26

On the trailing twelve months. Last full year: P/E 17.2× · P/S 3.2× · ROE 26.9%.

Section 09 · The stock

How has the stock performed?

The share price is down 1.0% over 1 year, up 64.5% over 3 years (18.1% a year) and up 124% over 5 years (17.5% a year). These are price changes excluding dividends, adjusted for splits and bonuses, to 20 Nov 2026; it is 20.1% below its 52-week high.

Adjusted close — 2020-01 to 2026-11₹ per share · split / bonus adjusted
0k4k₹2,0102020202120222023202420252026
Context

Over 5 years profit compounded at 34.3% a year while the stock returned 17.5% a year.

Rule STOCK_LAGGED_EARNINGS

Business vs stock — 5-year compound annual rate
Net profit34.3%/yrShare price17.5%/yr
1-year return
−1.0%
3-year return
+64.5%
5-year return
+123.7%
From 52-wk high
−20.1%
Section 10 · Technical data

What does the technical data say?

Price-action indicators as of 2026-11-20. Secondary to the fundamentals above — included for timing context, not as a signal.

vs 50-day avg
Below₹2,015
vs 200-day avg
Below₹2,232
RSI (14)
53.1neutral
MACD histogram
4.0
From 52-wk high
−20.1%
From 52-wk low
+4.4%
30-day volatility
16.2%ann.
6-month return
−12.1%
RSI (14) · 0–10053.1 — neutral
0305070100OVERSOLDOVERBOUGHT53.1
Section 11 · Open questions

What should I investigate further?

Observations the engine tagged watch or deteriorating — prompts for your own research, not conclusions.

  • Watch
    Volatile earnings
    Profit has swung sharply over 7 years (from ₹-1,509 to ₹5,355) — one year is a weak guide to the earnings power.
    EARNINGS_VOLATILE · conviction 65
  • Watch
    Cash conversion trending down
    Cash conversion (CFO ÷ profit) has averaged 1.11× over the last 3 profit-making years versus 2.66× before that.
    CASH_CONVERSION_DETERIORATING · conviction 64
  • Watch
    Reported profit carries a one-off
    FY2026 pre-tax profit includes a ₹558 exceptional charge (8.1% of PBT) — the underlying trend differs from the reported number.
    PROFIT_INCLUDES_EXCEPTIONALS · conviction 39
  • Cash-flow-statement facts are unavailable for FY2019, FY2020 — those filings predate SEBI's Cash Flow Statement disclosure requirement. All other loaded years carry full P&L, balance sheet and cash-flow data.
Section 12 · Reference

The numbers

The full statements, kept deliberately secondary. Every figure traces to a BSE Integrated Filing (inline XBRL); ratios are recomputed from the normalised facts.

Income & balance sheet — ₹ crore, consolidated
MetricFY19FY20FY21FY22FY23FY24FY25FY26
Revenue16,36915,37515,16316,40516,64220,01122,70827,958
Total income17,08215,85915,29916,54716,71520,13122,90428,382
EBITDA3,2462,8392,7034291,8713,9315,4799,240
Profit before tax1,5177531,675−1,3737162,4224,0156,873
Net profit615−2701,228−1,5094481,9363,3065,355
EPS (₹)34.3−6.027.1−33.69.542.072.0116.8
Net worth13,78912,58113,85812,22212,54314,37317,29422,513
Total debt8,2224,2863,0663,8444,2442,6705,0775,910
Operating cash flow——1,2391,0821,9343,4904307,546
Free cash flow——5621844732,574−1,2235,738
Key ratios — consolidated
RatioFY19FY20FY21FY22FY23FY24FY25FY26
Growth
Revenue growth YoY—-6.1-1.48.21.420.213.523.1
Profit growth YoY—-143.8—-222.9—332.370.862.0
Profitability
EBITDA margin %19.818.517.82.611.219.624.133.1
Net margin %3.6-1.78.0-9.12.79.614.418.9
Return on equity %4.5-2.09.3-11.63.614.420.926.9
Return on capital %9.89.610.7-7.56.016.221.931.0
Leverage & cash
Debt to equity0.600.340.220.310.340.190.290.26
Cash flow ÷ profit——1.01—4.321.800.131.41
Current ratio2.261.671.661.511.341.581.871.90
Financials: BSE Integrated Filing inline XBRL (SEBI taxonomy), normalised to standard metric keys. Prices: end-of-day — history loaded from NSE end-of-day files, new days from the BSE bhavcopy; raw OHLC preserved; a corporate-action factor produces the adjusted series. The insight engine writes factual observations from fixed rules — it does not make recommendations. Not investment advice.